Virus-like particles (VLPs) are self-assembled viral protein complexes that mimic the native
virus structure without being infectious. VLPs, similarly to wild type viruses, are able to …

Viral infectious diseases threaten human health and global stability. Several vaccine
platforms, such as DNA, mRNA, recombinant viral vectors, and virus-like particle-based …

The introduction of directly acting antiviral agents (DAAs) has produced significant
improvements in the ability to cure chronic hepatitis C infection. However, with over 2% of …

The development of virus-like particle (VLP) based vaccines for human papillomavirus,
hepatitis B and hepatitis E viruses represented a breakthrough in vaccine development …

Hepatitis C virus (HCV) infection is a major cause of chronic liver diseases that often
requires liver transplantation. The standard therapies are limited by severe side effects …

Hepatitis C virus (HCV) persistently infects approximately 71 million people globally. To
prevent infection a vaccine which elicits neutralizing antibodies against the virus envelope …

The significant public health problem of Hepatitis C virus (HCV) has been partially
addressed with the advent of directly acting antiviral agents (DAAs). However, the …

Hepatitis C Virus (HCV) infects 2% of the world's population and is the leading cause of liver
disease and liver transplantation. It poses a serious and growing worldwide public health …

Hepatitis C virus-like particles (VLPs) are being developed as a quadrivalent vaccine
candidate, eliciting both humoral and cellular immune responses in animal trials …

Background: Hepatitis C virus (HCV) causes acute and chronic human hepatitis infections.
Due to the high genetic diversity and high rates of mutations in the genetic material so far …